"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(pancuronium bromide) Injection
NOT FOR USE IN NEONATES
CONTAINS BENZYL ALCOHOL
THIS DRUG SHOULD BE ADMINISTERED BY ADEQUATELY TRAINED INDIVIDUALS FAMILIAR WITH ITS ACTIONS, CHARACTERISTICS, AND HAZARDS.
PAVULON® (pancuronium bromide) injection is a nondepolarizing neuromuscular blocking agent chemically designated as the aminosteroid 2 ß, 16 ß - dipiperidino-5α-androstane3α, 17-β diol diacetate dimethobromide.
The structural formula is:
PAVULON® (pancuronium bromide injection) is supplied as a sterile, isotonic, nonpyrogenic solution for injection. Each mL contains 1 mg or 2 mg pancuronium bromide, 2 mg sodium acetate and 1% benzyl alcohol as preservative. The solution is adjusted to isotonicity with sodium chloride and to a pH of 4 with acetic acid and/or sodium hydroxide; water is used as the solvent.
Last reviewed on RxList: 1/11/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Pavulon Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.